This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Dermatologic Disorders  • Dermatologic Disorders, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Brigitte Coras, MD; Christian Hafner, MD; Albrecht Reichle, MD; Ulrich Hohenleutner, MD; Rolf-Markus Szeimies, MD; Michael Landthaler, MD; Thomas Vogt, MD

Arch Dermatol. 2004;140:1504-1507.

Background  Kaposi sarcoma (KS) in patients who are seronegative and seropositive for human immunodeficiency virus is currently the most common malignant tumor in central Africa. It accounts for 50% of all tumors reported in central African countries. Owing to the rising number of patients and the limitations of current therapies, there is an urgent demand for new strategies to treat KS.

Observation  We describe a 42-year-old dark-skinned patient from Mozambique with endemic KS. The tumor was first diagnosed 8 years earlier when an ulcerated nodule appeared at his right ankle joint. Subsequently, multiple reddish brown nodules appeared on both feet and the left thigh. Results of dermatohistopathological analysis confirmed the diagnosis of KS. Topical therapies including cryotherapy, carbon-dioxide laser, and photodynamic therapy could not prevent new recurrences and further cutaneous dissemination. Therefore, a novel antiangiogenic systemic therapy was started that was previously shown to be effective in angiosarcomas other than KS. The regimen consists of the biomodulators pioglitazone hydrochloride and rofecoxib combined with a metronomic (daily) low-dose chemotherapy with trofosfamide. We observed a partial remission, which has been stable for 18 months. No significant toxic effects were observed.

Conclusion  The suggested antiangiogenic strategy has the potential to become a cheap, practical, feasible alternative treatment for endemic KS, particularly suitable for the outpatient setting.

Author Affiliations: Departments of Dermatology (Drs Coras, Hafner, Hohenleutner, Szeimies, Landthaler, and Vogt) and Hematooncology (Dr Reichle), University of Regensburg, Regensburg, Germany.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?